Drug Profile
JNJ 63823539
Alternative Names: JNJ63823539Latest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Covagen
- Developer Cilag GmbH International; Covagen
- Class Bispecific antibodies
- Mechanism of Action Interleukin-17 inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 May 2020 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Switzerland (SC, Injection)
- 28 Apr 2020 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Switzerland (IV, Infusion)
- 07 Apr 2017 Phase-I clinical trials in Rheumatoid arthritis in Switzerland (SC) before March 2017 )